H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) today and set a price target of $4. The company’s shares opened today at $0.92, close to its 52-week low of $0.23.
Livnat noted:
“We had always believed the Products (DBRUP) directive to Agile—to go reformulate Twirla, show improved adhesion, then prove bioequivalence to the current patch or do a new Phase 3 —was unnecessary. Based on all the data we’ve seen, we have never had reason to believe Twirla has an adhesion problem, and likely has better benefit-risk than the only approved contraceptive patch, Ortho Evra (now branded-generic Xulane), which does 1.7M Rx/year despite high-dose CV risk, unique black box safety warnings, and likely similar detachment rates (see below).”
According to TipRanks.com, Livnat is a 2-star analyst with an average return of 1.6% and a 49.4% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Agile Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.
See today’s analyst top recommended stocks >>
Based on Agile Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.34 million. In comparison, last year the company had a GAAP net loss of $7.1 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch for use in contraception. It offers its product candidate Twirla, which is an investigational non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.